Towards personalized treatments for the present and next generation
The aim of the hDMT is:
- 1.To develop innovative 3D human organ and disease models on chips that recapitulate healthy and diseased human tissue.
- 2.To enable valorization and stimulate implementation of these models as test systems for different purposes
- The main implementation in the development process of novel therapies, will be in drug testing in the latest preclinical stage before starting clinical trials, in the format of a “clinical trial on a chip”. This means that for a specific organ or disease model a number of chips will be available, each including a patient-derived organ/disease model derived from iPS cells isolated from a specific patient. In this way the real patient population is adequately represented in an in vitro form as “patients on a chip”. This will be done in a low throughput format. Using such an approach a blood-based diagnostic test can simultaneously be developed to predict whether a specific patient is likely to respond to the drug. Importantly, while patients can only “be used” once in a clinical trial, these in vitro “patients” can in principle be generated as often as needed.
The scope of the organ and disease models on chips is:
- - Drug development (a.o. drug toxicity screening, drug target discovery)
- - New diagnostics, cosmetics, life style devices
- - Food additives, analysis of environmental contaminants
The models are applicable to a wide range of human-specific diseases, with genetic and/or immunological compounds, leading to personalized medicine.